MAM
AVTX icon

MPM Asset Management’s Avalo Therapeutics AVTX Stock Holding History

MPM Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-207
Closed -$2.22M – 15
2016
Q1 		$2.22M Hold
207
– – 0.69% 10
2015
Q4 		$2M Buy
+207
New +$2.27M 0.36% 10

Other funds holding AVTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MPM Asset Management's AVTX Position: Q2 2016 in Review

MPM Asset Management sold out of Avalo Therapeutics (AVTX) in Q2 2016, closing a stake of 207 shares — an estimated $2.22M sold.

MPM Asset Management first reported a position in AVTX in Q4 2015 and held it in 2 quarters. The position peaked at $2.22M in Q1 2016. 5 funds tracked by Wall St. Rank hold AVTX as of Q2 2016.

  • MPM Asset Management reported no remaining Avalo Therapeutics position as of Q2 2016 after selling out during the quarter.
  • MPM Asset Management sold 207 Avalo Therapeutics shares in Q2 2016, an estimated $2.22M.
  • MPM Asset Management first reported a position in Avalo Therapeutics in Q4 2015 and held it in 2 quarters.
  • MPM Asset Management's Avalo Therapeutics position peaked at $2.22M in Q1 2016.
  • 5 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2016.

Based on MPM Asset Management's 13F filing for Q2 2016, filed 8 Aug 2016.